Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA342892
Max Phase: Preclinical
Molecular Formula: C18H23IO2
Molecular Weight: 398.28
Molecule Type: Small molecule
Associated Items:
ID: ALA342892
Max Phase: Preclinical
Molecular Formula: C18H23IO2
Molecular Weight: 398.28
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 16alpha-iodo-17beta-Estradiol
Synonyms from Alternative Forms(1):
Canonical SMILES: C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](I)[C@@H]2O
Standard InChI: InChI=1S/C18H23IO2/c1-18-7-6-13-12-5-3-11(20)8-10(12)2-4-14(13)15(18)9-16(19)17(18)21/h3,5,8,13-17,20-21H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,17+,18+/m1/s1
Standard InChI Key: SSYGGPAGDDGXAF-ZXXIGWHRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 398.28 | Molecular Weight (Monoisotopic): 398.0743 | AlogP: 4.02 | #Rotatable Bonds: 0 |
Polar Surface Area: 40.46 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.33 | CX Basic pKa: | CX LogP: 4.46 | CX LogD: 4.46 |
Aromatic Rings: 1 | Heavy Atoms: 21 | QED Weighted: 0.51 | Np Likeness Score: 2.05 |
1. Heiman DF, Senderoff SG, Katzenellenbogen JA, Neeley RJ.. (1980) Estrogen receptor based imaging agents. 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens., 23 (9): [PMID:7411555] [10.1021/jm00183a007] |
2. Landvatter SW, Katzenellenbogen JA, McElvany KD, Welch MJ.. (1982) (2R*,3S*)-1-[125I]Iodo-2,3-bis(4-hydroxyphenyl)pentane ([125I]iodonorhexestrol) and (2R*,3S*)-1-[77Br]Bromo-2,3-bis(4-hydroxyphenyl)pentane ([77Br]bromonorhexestrol), two gamma-emitting estrogens that show receptor-mediated uptake by target tissues in vivo., 25 (11): [PMID:6292424] [10.1021/jm00353a007] |
3. Levesque C, Merand Y, Dufour JM, Labrie C, Labrie F.. (1991) Synthesis and biological activity of new halo-steroidal antiestrogens., 34 (5): [PMID:2033587] [10.1021/jm00109a014] |
4. DaSilva JN, van Lier JE.. (1990) Synthesis and structure-affinity of a series of 7 alpha-undecylestradiol derivatives: a potential vector for therapy and imaging of estrogen-receptor-positive cancers., 33 (1): [PMID:2296033] [10.1021/jm00163a066] |
Source(1):